Alpha-synuclein seed amplification assay longitudinal outcomes in Lewy body disease spectrum.
Altered Empathy Processing in Frontotemporal Dementia.
Diagnosis of Alzheimer’s disease using plasma biomarkers adjusted to clinical probability.
A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests.
Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease.
Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment
MRI Signature of α-Synuclein Pathology in Asymptomatic Stages and a Memory Clinic Population
Revised criteria for the diagnosis and staging of Alzheimer’s disease
Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology
Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment
Disease staging of Alzheimer’s disease using a CSF-based biomarker model
A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings
Highly Accurate Blood Test for Alzheimer’s Disease Comparable or Superior to Clinical CSF Tests.
Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies.
The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases.
DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease.
Cognitive effects of Lewy body pathology in clinically unimpaired individuals.
Clinical effects of Lewy body pathology in cognitively impaired individuals.
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease.